Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alkermes 2Q12 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Alkermes 2Q12

Elan portfolio makes contribution

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alkermes 2Q12 

2Q Revenues: $72.0 million (+46%)

2Q Loss: $22.3 million (loss of $7.7 million 2Q11)

Comments: Manufacturing and royalty revenues from Risperdal Consta were $44.3 million in the quarter, up 5%. Vivitrol sales were $9.9 million, compared to $6.5 million, up 52%. Alkermes completed the merger with Elan Drug Technologies (EDT) on Sept. 16, 2011. The EDT portfolio contributed $9.1 million to revenues in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters